180 Life Sciences EBIT

As of the most recent data (March 2026), ATNF shows a EBIT of $-9.8B. That compares with $-9.8M in the prior-year period — down 100563.4% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ATNF's EBIT is now $-9.8B (was $-9.8M) — a 100563.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether 180 Life Sciences is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. 180 Life Sciences is at $-9.8B, which is lower that average. That is roughly 142.1% below the sector mean. Use the comparison chart on this page to see how ATNF stacks up against individual peers as well.

Tracking ATNF's ebit over time shows whether 180 Life Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-9.8B That compares with $-9.8M in the prior-year period — down 100563.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has 180 Life Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-9.8B) with ownership activity and broader fundamentals.